Cisplatin + nintedanib + pemetrexed + placebo

Author: nykv

August undefined, 2024

WebPatients received oral nintedanib (150 mg or 200 mg twice daily for 12 weeks) or placebo, in addition to usual neoadjuvant chemotherapy with intravenous gemcitabine 1000 mg/m 2 on days 1 and 8 and intravenous cisplatin 70 mg/m 2 on day 1 of a 3-weekly cycle. The primary endpoint was pathological complete response rate, assessed at cystectomy or ... WebDec 4, 2014 · At least one dose reduction of nintedanib or placebo was required by 18.6% and 6.3% of patients in the nintedanib plus docetaxel and placebo plus docetaxel groups, respectively. Gastrointestinal AEs …

Review of nintedanib plus pemetrexed/cisplatin in patients with ...

WebOct 1, 2024 · PDF On Oct 1, 2024, Federica Grosso and others published SPS-7Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial Find ... WebSep 11, 2024 · Treatment with pemetrexed and cisplatin and either nintedanib or matching placebo was given in 21-day courses. … grant wahl height

Nintedanib with Pemetrexed and Cisplatin for Pleural Mesothelioma

WebNintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, … WebOther strategies to target VEGF have included the use of the angiokinase inhibitor nintedanib in combination with cisplatin and pemetrexed chemotherapy in the Phase III, randomised LUME-Meso trial. 40 This failed to demonstrate a benefit for median PFS for the addition of nintedanib (6.8 versus 7.0 months, HR 1.01 95% CI 0.79–1.30, p = 0.914). WebGültigkeitsbereich: Leitlinie Tumorzentrum Oberösterreich Bronchuskarzinom Paz-Ares L, Gridelli C et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non- small-cell lung cancer (PARAMOUNT): a double-blind ... grant wahl death rumors

Optimal Therapy of Advanced Stage Mesothelioma SpringerLink

Clinical development of nintedanib for advanced non-small-cell …

WebA subsequent analysis of the available intent-to-treat population based on independent review data showed a PFS benefit for patients treated with nintedanib plus pemetrexed compared with placebo plus pemetrexed (median PFS of 4.4 months versus 3.6 months; hazard ratio [HR] of 0.83 with a 95% confidence interval [CI] of 0.70–0.99; P=0.04), but ... WebJul 24, 2013 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double … chipotle pepper usesWebOct 15, 2024 · which tested the addition of nintedanib to pemetrexed and cisplatin in 87 patients with unresectable malignant pleural mesothelioma with epithelioid and biphasic histology, reported an overall survival of 14·2 months (95% CI 12·3–20·9) in the control group and 18·3 months (15·2–28·8) in the experimental group. grant wahl investigation

"WebMar 27, 2024 · For unresectable MPM, a regimen of pemetrexed (Pem) and cisplatin (Cis) was approved as the standard of care in first-line treatment by the FDA in 2004 . Currently, numerous studies are being conducted to explore the efficacy of novel agents and regimens for MPM first-line treatment. ... Regardless, any kind of therapy other than placebo may … " - Cisplatin + nintedanib + pemetrexed + placebo

Cisplatin + nintedanib + pemetrexed + placebo

WebNintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, … WebJun 5, 2024 · Nintedanib Chemo Combo Promising for Malignant Mesothelioma Frontline treatment with nintedanib plus pemetrexed and cisplatin improved progression-free …

Did you know?

WebMay 15, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME … WebMay 16, 2013 · This randomized, double-blinded study evaluated nintedanib – a triple angiokinase inhibitor – plus pemetrexed compared to pemetrexed plus placebo in patients with advanced non-squamous NSCLC not responding to, or who progressed after, first-line chemotherapy. 20 LUME-Lung 2 did not pass the pre-defined interim futility analysis from ...

WebApr 1, 2024 · Request PDF On Apr 1, 2024, Antoinette J. Wozniak and others published Short report of a phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM) Find, read and cite all ... WebJan 1, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2024; 7: 569-580 View in Article Scopus (84) PubMed Summary Full Text Full Text PDF Google Scholar Article Info

WebReview of nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial J Thorac Dis . 2024 Sep;10(Suppl 26):S3124-S3127. doi: 10.21037/jtd.2024.07.105. WebDec 1, 2024 · Placebo, pemetrexed 500 mg/m 2, and investigator's choice of cisplatin 75 mg/m 2 or carboplatin AUC 5 mg/mL/min intravenously on Day 1 of each 21-day cycle for 4 cycles followed by placebo and pemetrexed 500 mg/m 2 intravenously every 3 weeks.

WebApr 11, 2024 · Nintedanib doses were permitted to be reduced to 150 mg, 100 mg, or 50 mg (or to 100 mg or 50 mg for patients with GFR 40–60 mL/min). Both gemcitabine and …

WebMay 30, 2024 · Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). Anna K. Nowak. x. Anna K. Nowak. Search for articles by this author , Federica Grosso. x ... chipotle pfefferWebJul 1, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double … grant wahl high schoolWebJul 1, 2024 · Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double … grant wahl health issuesWebApr 7, 2024 · This is a Phase II trial assessing the efficacy of nintedanib, an oral multi-targeted kinase inhibitor, in patients with recurrent malignant pleural mesothelioma. The drug was well tolerated but the activity was modest with no responses and 40% stable disease at 8 weeks. grant wahl health problemsWebApr 9, 2024 · Introduction: Mesothelioma is a rare and aggressive cancer that affects the lining of the lungs, abdomen, or heart. It is most commonly caused by exposure to asbestos fibers, and unfortunately, it has a poor prognosis. The standard treatment options for mesothelioma include surgery, chemotherapy, and radiation therapy, but these … grant wahl lebron articleWebThis is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma. chipotle peppers with adobo sauceWebThe intervention group received up to six cycles of pemetrexed and cisplatin plus nintedanib 200 mg twice daily while the control group received chemotherapy plus … grant wahl myocarditis